Literature DB >> 32329221

Type and dose of heparin in Covid-19: Reply.

Jecko Thachil1, Ning Tang2, Satoshi Gando3, Anna Falanga4, Marcel Levi5, Cary Clark6, Toshiaki Iba7, Marco Cattaneo8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32329221     DOI： 10.1111/jth.14870

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  8 in total

1.  The delights and perils of publishing, knowledge-sharing and critique during a pandemic: Observations from COVID-19 coagulopathies.

Authors:  Sajida Kazi; A Kinga Malinowski; Maha Othman
Journal:  Thromb Res       Date:  2020-05-16       Impact factor: 3.944

Review 2.  COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate.

Authors:  Sukrita Bhattacharjee; Mainak Banerjee; Rimesh Pal
Journal:  Indian Pediatr       Date:  2020-06-24       Impact factor: 1.411

3.  Portal Vein Thrombosis-a Rare Complication of SARS-CoV-2 Infection.

Authors:  Neeraj Sharma; Rajat Shukla; Kunal Kumar; Sumeet Arora; Rachna Warrier; Subin Philip
Journal:  SN Compr Clin Med       Date:  2021-04-07

Review 4.  The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients.

Authors:  Edyta Reichman-Warmusz; Oliwia Warmusz; Romuald Wojnicz
Journal:  Open Med (Wars)       Date:  2022-01-24

Review 5.  Thromboembolic disease in COVID-19 patients: A brief narrative review.

Authors:  Samhati Mondal; Ashley L Quintili; Kunal Karamchandani; Somnath Bose
Journal:  J Intensive Care       Date:  2020-09-14

6.  Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.

Authors:  Antonio Chistolini; Franco Ruberto; Francesco Alessandri; Cristina Santoro; Francesco Barone; Maria Cristina Puzzolo; Giancarlo Ceccarelli; Maria L De Luca; Massimo Mancone; Domenico Alvaro; Fabio M Pulcinelli; Maurizio Martelli; Robin Foà; Francesco Pugliese
Journal:  Br J Haematol       Date:  2020-07-28       Impact factor: 8.615

7.  Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.

Authors:  Massimo Mattioli; Devis Benfaremo; Mauro Mancini; Luciano Mucci; Paola Mainquà; Antonio Polenta; Patrizia Maria Baldini; Francesca Fulgenzi; Donatella Dennetta; Samuele Bedetta; Lorenzo Gasperoni; Alessandro Caraffa; Gabriele Frausini
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 5.221

Review 8.  Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.

Authors:  Rami A Al-Horani
Journal:  Am J Cardiovasc Drugs       Date:  2020-12       Impact factor: 3.283
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.